糖尿病視網膜病變市場：現況分析與預測（2023-2030）

Diabetic Retinopathy Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年03月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於老年人口的增加，糖尿病視網膜病變市場預計在預測期內將以 9.1% 的複合年增長率強勁增長。例如，根據美國人口普查局的數據，到2050年，全球65歲及以上的人口將達到16億，是2018年人口的兩倍多。同樣，世界衛生組織 (WHO) 估計，到 2050 年，60 歲及以上的人口數量將從 2017 年的 9.62 億增加近兩倍，達到 21 億。這些統計數據表明，世界各地的老年人口正在顯著增加。傳播對這種疾病的認識非常重要，以便患者能夠及早診斷並尋求適當的醫療照護。導致糖尿病視網膜病變發病和進展的因素包括長期糖尿病、血糖控制不佳、高血壓、膽固醇水平升高、吸煙、家族史和遺傳傾向。此外，不良的生活習慣也促進了糖尿病視網膜病變市場的成長。

依類型分為增殖性糖尿病視網膜病變和非增殖性糖尿病視網膜病變。非增殖性糖尿病視網膜病變領域由於近年來盛行率較高，到2022年將佔大部分市場佔有率。在非增殖性糖尿病視網膜病變中，長期暴露於高血糖會損害視網膜中的小血管。然而，隨著病情的進展，症狀包括視力模糊、閱讀困難和辨別顏色困難。糖尿病患者數量的增加導致了這種疾病在全球範圍內的傳播。因此，在2022年的預測期內，非增殖性糖尿病視網膜病變類別佔據了市場的大部分佔有率。

根據應用，市場分為診斷和治療。預計治療領域將在預測期內顯著成長。治療領域是由不斷進步的技術所推動的。糖尿病視網膜病變市場治療領域的成長是由疾病盛行率的增加、醫療保健服務的改善以及對早期介入和聯合治療方法的日益重視所推動的。對研發的持續投資，以及改善患者獲得有效治療的努力，預計將在預測期內維持治療產業的成長軌跡。因此，預計在預測期內，治療領域將在市場上佔據顯著地位。

為了更瞭解市場，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）和亞太地區（中國、日本、印度、亞太地區其他地區）和世界其他國家是根據其在世界上的存在進行分析的。2022年糖尿病視網膜病變市場由北美主導。有幾個因素正在推動該地區的市場發展，包括糖尿病視網膜病變病例數量的增加、創新的仿製藥供應、人們對糖尿病視網膜病變的認識不斷提高、企業合作夥伴關係以及該地區老年人口的增加。例如，40歲以上有894萬人患有糖尿病視網膜病變，40歲以上有171萬人患有威脅視力的糖尿病視網膜病變。依地區劃分，2022年糖尿病視網膜病變市場將由北美主導。

Diabetic retinopathy is a complication of diabetes that affects the eyes. It occurs when high blood sugar levels damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. As the global population ages, the incidence of diabetic retinopathy is expected to rise, thus fueling the demand for treatment options. The rising awareness about diabetic retinopathy also plays a significant role in driving growth in the diabetic retinopathy market. Increased awareness efforts by government health agencies, non-profit organizations, and healthcare providers have raised public consciousness about the importance of regular eye examinations for individuals with diabetes. Additionally, technological advancements in drug development have increased in recent years further driving the market growth.

The Diabetic Retinopathy Market is expected to grow at a strong CAGR of 9.1% during the forecast period owing to the rising geriatric population. For instance, according to the U.S. Census Bureau, the global population aged 65 and older will reach 1.6 billion by 2050, more than double the population in 2018. Similarly, the World Health Organization (WHO) estimates that the number of people aged 60 and above will nearly triple by 2050, from 962 million in 2017 to 2.1 billion. These statistics indicate a significant increase in the geriatric population worldwide. Spreading awareness about the disease is very crucial to help patients diagnose the disease in early stages and search for appropriate medical treatment. Driving factors contributing to the development and progression of diabetic retinopathy are longer duration of diabetes, poor blood sugar control, high blood pressure, elevated cholesterol levels, smoking, family history, and genetic predisposition. The surge in poor lifestyles also contributes to the growth of the diabetic retinopathy market.

Based on types, the market is bifurcated into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy segment held the majority share of the market in 2022 because of the higher prevalence of the disease in recent years. In non-proliferative diabetic retinopathy, the small blood vessels in the retina are damaged due to prolonged exposure to high levels of blood sugar. However, if the condition progresses, patients experience blurred vision, difficulty reading, and difficulty in differentiating colors. Growing cases of diabetes are leading to the growth of the disease worldwide. Hence, the non-proliferative diabetic retinopathy category held the majority share of the market in the year 2022 during the forecast period.

Based on application, the market is bifurcated into diagnosis and treatment. The treatment segment is expected to grow at a significant rate in the forecast period. The driving factor for the treatment segment is the growing technological advancements. The growth of the treatment segment in the diabetic retinopathy market is driven by increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Continued investment in research and development, along with efforts to improve patient access to effective treatments, will likely sustain the growth trajectory of the treatment segment in the forecast period. Thus, the treatment segment is expected to gain prominence in the market in the forecast period.

For a better understanding, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market of diabetic retinopathy in 2022. Several factors such as the growing cases of diabetic retinopathy, availability of innovative generics, growing awareness of diabetic retinopathy, company collaborations, and the rising geriatric population in the region are driving the market in the region. For instance, there were 8.94 million people aged >=40 years with diabetic retinopathy and 1.71 million people aged >=40 years with vision-threatening diabetic retinopathy. North America dominated the diabetic retinopathy market among regions in the year 2022.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd; Novartis AG; Regeneron Pharmaceuticals Inc.; Bayer AG; Coherus BioSciences, Inc.; KODIAK SCIENCES INC.; HANLIM PHARM.CO.LTD.; Sanofi; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.

1.MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Diabetic Retinopathy Market
2.2.Research Methodology of the Diabetic Retinopathy Market
2.3.Respondent Profile

3.MARKET SYNOPSIS

4.EXECUTIVE SUMMARY

5.IMPACT OF COVID-19 ON THE DIABETIC RETINOPATHY MARKET

6.DIABETIC RETINOPATHY MARKET REVENUE (USD BN), 2020-2030F

7.MARKET INSIGHTS BY TYPE

7.1.Proliferative Diabetic Retinopathy
7.2.Non-proliferative Diabetic Retinopathy

8.MARKET INSIGHTS BY APPLICATION

8.1.Diagnosis
- 8.1.1.Visual Acuity Testing
- 8.1.2.Fluorescein Angiography
- 8.1.3.Optical Coherence Tomography (OCT)
- 8.1.4.Others
8.2.Treatment
- 8.2.1.Anti-VEGF Drugs
- 8.2.2.Laser Surgeries
- 8.2.3.Others

9.MARKET INSIGHTS BY REGION

9.1.North America
- 9.1.1.U.S.
- 9.1.2.Canada
- 9.1.3.Rest of North America
9.2.Europe
- 9.2.1.Germany
- 9.2.2.U.K.
- 9.2.3.France
- 9.2.4.Italy
- 9.2.5.Spain
- 9.2.6.Rest of Europe
9.3.Asia-Pacific
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.India
- 9.3.4.Rest of Asia-Pacific
9.4.Rest of World